Repligen (RGEN) Competitors

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Do analysts rate BIIB or RGEN?

Biogen presently has a consensus price target of $213.15, suggesting a potential upside of 82.33%. Repligen has a consensus price target of $178.64, suggesting a potential upside of 42.00%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	18 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.42
Repligen	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57

Is BIIB or RGEN more profitable?

Biogen has a net margin of 16.87% compared to Repligen's net margin of -4.64%. Biogen's return on equity of 14.98% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	16.87%	14.98%	8.76%
Repligen	-4.64%	4.21%	2.94%

Does the MarketBeat Community prefer BIIB or RGEN?

Biogen received 1402 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 67.32% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Biogen	Outperform Votes 1816 71.41%	Underperform Votes 727 28.59%
Repligen	Outperform Votes 414 67.32%	Underperform Votes 201 32.68%

Do insiders and institutionals hold more shares of BIIB or RGEN?

87.9% of Biogen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 1.2% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has better earnings & valuation, BIIB or RGEN?

Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.77	$1.63B	$11.19	10.45
Repligen	$634.44M	11.13	$35.60M	-$0.51	-246.67

Does the media favor BIIB or RGEN?

In the previous week, Biogen had 28 more articles in the media than Repligen. MarketBeat recorded 39 mentions for Biogen and 11 mentions for Repligen. Biogen's average media sentiment score of 1.00 beat Repligen's score of 0.89 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, BIIB or RGEN?

Biogen has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Summary

Biogen beats Repligen on 13 of the 18 factors compared between the two stocks.